Octreotide in hepatorenal syndrome: A randomized, double‐blind, placebo‐controlled, crossover study
Gilles Pomier‐Layrargues, Sarto C. Paquin, Ziad Hassoun, Michel Lafortune, Albert Tran – 30 December 2003 – The hepatorenal syndrome (HRS) is related to vasoconstriction of the renal cortex induced by systemic hypovolemia that follows splanchnic vasodilatation as the primary event in the cascade of hemodynamic changes associated with portal hypertension. We evaluated the effects of octreotide, a splanchnic vasoconstrictor, on HRS in cirrhotic patients.